HOME ·

FOSUN PHARMA

FOSUN PHARMA (02196.HK): Registration application for new specification of HLX14 denosumab biosimilar accepted by NMPA
Tags：
FOSUN PHARMA02196.HKR&D Progress
2026-09-11
FOSUN PHARMA (02196.HK): FXS5626 Approved for Phase II/III Trial in Non-Segmental Vitiligo
Tags：
FOSUN PHARMA02196.HKR&D Progress
2026-09-08
FOSUN PHARMA (02196.HK): Sells 6% Stake in India's Gland Pharma for Approximate USD 294 Million
Tags：
FOSUN PHARMA02196.HKEquity Disposal
2026-09-07
FOSUN PHARMA (02196.HK): Licensed drug weliteitumab injection (GR1803) granted conditional approval for relapsed or refractory multiple myeloma
Tags：
FOSUN PHARMA02196.HKClinical Progress
2026-08-27
FOSUN PHARMA (02196.HK): Repurchases 217,000 H shares for approximately HKD 3.587 million
Tags：
FOSUN PHARMA02196.HKShare Buyback
2026-08-27
Fosun Pharma (02196.HK): DM1001 Preparation Obtains Clinical Trial Approval
Tags：
FOSUN PHARMA02196.HK
2026-07-24
Fosun Pharma (02196.HK): Controlled Subsidiary’s HLX3902 Injection Obtains Clinical Trial Approval
Tags：
FOSUN PHARMA02196.HK
2026-06-17
FOSUN PHARMA (02196.HK): Taohong Siwu Decoction Granules Registration Application Accepted by NMPA
Tags：
FOSUN PHARMA02196.HKdrug registration application
2026-05-13